Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Otto

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
Transplantation|August 27, 2015
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?Bo-Göran Ericzon, Henryk E Wilczek, Marie Larsson, et al.
Hepatology (Baltimore, Md.)|June 28, 2019
Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 PatientsDaniel J Firl, Kazunari Sasaki, Vatche G Agopian, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|March 23, 2013
Reperfusion of liver graft during transplantation: techniques used in transplant centres within Eurotransplant and meta-analysis of the literatureGiulia Manzini, Michael Kremer, Philipp Houben, et al.
Clinical and Translational Medicine|June 15, 2024
Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic markerPatrick S Plum, Timo Hess, Denis Bertrand, et al.
BMC Cancer|May 13, 2010
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinomaAndreas A Schnitzbauer, Carl Zuelke, Christian Graeb, et al.
Transplantation|November 12, 2015
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 TrialEdward K Geissler, Andreas A Schnitzbauer, Carl Zülke, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
Transplantation|August 27, 2015
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?Bo-Göran Ericzon, Henryk E Wilczek, Marie Larsson, et al.
Hepatology (Baltimore, Md.)|June 28, 2019
Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 PatientsDaniel J Firl, Kazunari Sasaki, Vatche G Agopian, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|March 23, 2013
Reperfusion of liver graft during transplantation: techniques used in transplant centres within Eurotransplant and meta-analysis of the literatureGiulia Manzini, Michael Kremer, Philipp Houben, et al.
Clinical and Translational Medicine|June 15, 2024
Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic markerPatrick S Plum, Timo Hess, Denis Bertrand, et al.
BMC Cancer|May 13, 2010
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinomaAndreas A Schnitzbauer, Carl Zuelke, Christian Graeb, et al.
Transplantation|November 12, 2015
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 TrialEdward K Geissler, Andreas A Schnitzbauer, Carl Zülke, et al.
Pageof 10